In addition to the development deal, Cannassure will now have the exclusive right to use Lipidor’s innovative AKVANO® topical spray technology.
According to Cannassure’s estimates, the combined treatment market for all of these chronic illnesses and symptoms could be worth over $50 billion by 2027.
The feasibility study looked at different models to see whether Cannassure’s cannabinoids were compatible with Lipidor’s topical drug delivery spray technology.
Cannassure said that it has proven that the cannabinoids can be well combined into the AKVANO system, into a homogeneous, uniform and stable formulation.
Cannassure CEO Ran Amir stated that the company looked forward to the joint development process, saying that “The AKVANO non-touch application paired with an excellent uptake of active substance in different skin layers opens up the…
Original Author Link click here to read complete story..
In addition to the development deal, Cannassure will now have the exclusive right to use Lipidor’s innovative AKVANO® topical spray technology.
According to Cannassure’s estimates, the combined treatment market for all of these chronic illnesses and symptoms could be worth over $50 billion by 2027.
The feasibility study looked at different models to see whether Cannassure’s cannabinoids were compatible with Lipidor’s topical drug delivery spray technology.
Cannassure said that it has proven that the cannabinoids can be well combined into the AKVANO system, into a homogeneous, uniform and stable formulation.
Cannassure CEO Ran Amir stated that the company looked forward to the joint development process, saying that “The AKVANO non-touch application paired with an excellent uptake of active substance in different skin layers opens up the…
